LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
LARIMAR THERAPEUTICS, INC. (LRMR) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $300.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $300.00K.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $5.80M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $400.00K.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $200.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $5.80M 10-Q · filed 2026-05-14 |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $200.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-30 |
| 2024-12-31 | $400.00K 10-K · filed 2025-03-24 |
| 2024-09-30 | $7.40M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $9.80M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.00M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $900.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $400.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $400.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $300.00 10-K · filed 2023-03-14 |
| 2022-09-30 | $100.00 10-Q · filed 2022-11-10 |
| 2021-12-31 | $200.00K 10-K · filed 2022-03-25 |
| 2021-09-30 | $400.00K 10-Q · filed 2021-11-12 |
| 2021-03-31 | $4.40M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $15.50M 10-K · filed 2021-03-04 |
| 2020-09-30 | $5.30M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $400.00 10-Q · filed 2020-08-14 |
| 2016-12-31 | $1.04M 10-K · filed 2017-03-10 |
| 2015-12-31 | $3.92M 10-K · filed 2016-03-15 |
| 2014-12-31 | $222.58M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |